Electronic Letters to:
|
|
E-letters: Electronic letters published:
-
![[Read eLetter]](/icons/misc/sectionDOWN.gif)
Response to Phase I/II study of capecitabine and vinorelbine in pretreated patients with MBC
- Woo Kun Kim, [Jin-Hee Ahn] and [Sung-Bae Kim] (28 July 2005)
|
|
|||
|
Woo Kun Kim, Division of Oncology, Asan Medical Center, University of Ulsan College of Medicine 388-1, Pungnapdong, Songpagu, Seoul, Republic of Korea, [Jin-Hee Ahn] and [Sung-Bae Kim]
Send e-letter to journal:
|
The result of your study [1] of capecitabine and vinorelbine in metastatic breast cancer patients, who had been treated with anthracycline and taxane previously, is quite similar to our study result although the dosage of capecitabine was higher than yours as you correctly quoted as an abstract [2]. This abstract was published as a full article in August 2004 [3]. All of our 44 patients had anthracycline and taxane previously and the overall response rate was 50% with median progression free survival being 5.3 months. As you correctly described, the incidence of hand foot syndrome (HFS) of capecitabine and vinorelbine appears to be much less and milder than O¡¯Shaughnessy¡¯s capecitabine and docetaxel combination regimen which gave 24% grade III HFS [4]. The HFS of your study appears to be similar to ours. The incidence of grade II and III HFS in our study were 5.1% and 1.7%, respectively, out of total 235 cycles. Grade III and IV neutropenia occurred in 26.8% and 1.7% cycles and only one patient out of 44 had febrile neutropenia whereas O¡¯Shaughnessy¡¯s capecitabine and docetaxel regimen had 16%. Grade III stomatitis and diarrhea was virtually none as in your study compared to 17% and 14%, respectively, with the capecitabine and docetaxel regimen. Your study and ours support the possibility that capecitabine and vinorelbine combination could be as effective as capecitabine and docetaxel, yet with far less toxicity, and it warrants further study comparing with capecitabine and docetaxel regimen. References 1.Welt A, von Minckwitz G, Oberhoff C, et al. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 2005; 16: 64-69 2.Ahn JH, Kim SB, Ahn SH, et al. Phase II study of capecitabine and vinorelbine in anthracycline and taxane pretreated breast cancer: Final results. Proc Am Soc Clin Oncol 2003; 22: 54 (Abstr 216) 3.Ahn JH, Kim SB, Kim TW, et al. Capecitabine and vinorelbine in patients previously treated with anthracycline and taxane. J Kor Med Sci. 2004; 19: 547-553 4.O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline- pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-2823 Conflict of Interest:None declared |
|||